SCHEMBL25410271

SCHEMBL25410271

COC(=O)C(C(=O)OC(C)(C)C)c1cc(Cl)nc(Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
KMT2A Q03164 1/20 0.52
MAPK1 P28482 1/20 0.36
STK17B O94768 1/20 0.35
STK17A Q9UEE5 1/20 0.35
NPR3 P17342 2/20 0.34
ATR Q13535 1/20 0.33
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
SYK P43405 1/20 0.32
ATF1 P18846 1/20 0.32
NFKB1 P19838 1/20 0.32
FPR2 P25090 1/20 0.31
SCN9A Q15858 1/20 0.31
AAK1 Q2M2I8 2/20 0.31
TRPA1 O75762 1/20 0.31
APP P05067 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30598919 1.00 LMNA (0.52) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL21392066 0.88 KMT2A (0.48) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL21392136 0.84 LMNA (0.45) LMNAKMT2AMAPK1NPR3ATF1
SCHEMBL31292319 0.84 LMNA (0.48) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL21373731 0.80 LMNA (0.51) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL21392096 0.78 LMNA (0.52) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL1854901 0.76 MAPK1 (0.41) LMNAKMT2AMAPK1KDM4E
SCHEMBL31292396 0.76 KMT2A (0.89) LMNAKMT2AMAPK1ATRCA12
SCHEMBL29254962 0.72 KMT2A (0.46) LMNAKMT2AMAPK1STK17BSTK17A
SCHEMBL29215963 0.71 KMT2A (0.48) LMNAKMT2AMAPK1ATRAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 US disclosed
EP-4490152-A1 ACTIVATORS OF EFFECTOR T CELLS Orum Therapeutics Inc. (KR) 2025-01-15 EP disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 WO disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS CBLB, CBL, CBLC LMNA 3531/4885KMT2A 1486/4885MAPK1 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.